Get started
Author

Anne-Laure Désage

Observed names: A-L. desage, A.-L. Desage, A.-L. Désage, A.L. Desage, Anne Laure Desage, Anne Laure Désage, Anne-Laure Desage
Observed institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Centre Léon Bérard, Institute Cancer De La Loire Lucien Neuwirth, Centre de Recherche en Cancérologie de Lyon, Centre Hospitalier Universitaire de Saint-Étienne, Université Jean Monnet, Université Jean Monnet
ORCID: 0009-0008-7778-6642
Observed ORCID: 0009-0008-7778-6642
OpenAlex ID: A5000308605
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
2022 · Anne-Laure Désage, Camille Léonce, et al. · Frontiers in Oncology · 60
PDF
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
2021 · Anne-Laure Désage, Georgia Karpathiou, et al. · Cancers · 33
PDF
Vaccination and Immune Checkpoint Inhibitors
2020 · Anne-Laure Desage, Wafa Bouleftour, et al. · American Journal of Clinical Oncology · 24
Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature
2021 · Anne-Laure Desage, Wafa Bouleftour, et al. · Translational Lung Cancer Research · 20
PDF
Spread Through Air Spaces in Stage I to III Resected Lung Adenocarcinomas
2024 · David Laville, Anne-Laure Désage, et al. · The American Journal of Surgical Pathology · 12
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
2024 · Anne-Laure Désage, Michael Duruisseaux, et al. · Cancer Treatment Reviews · 11
Adjuvant chemotherapy for completely resected IIA–IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice
2022 · Anne-Laure Désage, Claire Tissot, et al. · Translational Lung Cancer Research · 11
PDF
Prognostic role of immune microenvironment in pleural metastases from breast and lung adenocarcinomas
2022 · Georgia Karpathiou, Jonas Benli, et al. · Annals of Translational Medicine · 7
PDF
Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer
2024 · Laurent Bertoletti, Ludovic Lafaie, et al. · Expert Review of Respiratory Medicine · 5
OA02.01 Selective Translation of PBK (PDZ-Binding Kinase) is a Novel Mechanism of Drug Tolerance to Targeted Therapies in EGFR-Mutant Lung Cancer
2025 · Camille Léonce, Anne-Laure Desage, et al. · Journal of Thoracic Oncology · 1
Haemoptysis risk in lung cancer associated thrombosis (L-CAT) patients who initiated anticoagulant therapy.
2024 · Christophe Marie-Sainte, Anne-Laure Desage, et al. · 1
Traitement standard des stades III non résécables
2023 · P. Fournel, A.L. Desage, et al. · Revue des Maladies Respiratoires Actualités · 1
Value of immunohistochemistry in crushed areas of pulmonary neuroendocrine carcinoma
2022 · Hava Kuçuk, David Laville, et al. · Experimental and Molecular Pathology · 1
Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study
2026 · Thomas Pierret, Jean-Bernard Auliac, et al. · Current Oncology
Impact of local treatment on survival outcomes in patients with metastatic lung cancer with oligoprogression undergoing immunotherapy
2026 · Barbara Domenach, Valentine Mismetti, et al. · Swiss Medical Weekly
Hemoptysis risk in lung cancer associated thrombosis patients who initiated anticoagulant therapy
2026 · Christophe Marie-Sainte, Anne-Laure Desage, et al. · Respiratory Medicine and Research
SMARCA4-deficient Non-small Cell Lung Carcinoma Harboring ALK Fusion
2025 · Anne-Laure Désage, Simon Pointel, et al. · Applied immunohistochemistry & molecular morphology
Maladies thromboemboliques et cancer du poumon
2025 · G. Poenou, C. Marie-Sainte, et al. · Revue des Maladies Respiratoires Actualités
2007P Tolerance and efficacy of targeted therapies after immunotherapy in metastatic non-small cell lung cancer with molecular alterations: TOXIMAD GFPC 04-2022 study
2025 · T. Pierret, J.B. Auliac, et al. · Annals of Oncology
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)
2025 · Romain Corre, Chantal Decroisette, et al. · Clinical Lung Cancer
Analyse en vie réelle des patients atteints de cancer bronchique non à petites cellules transloqués ROS1 (Explore ALK, cohorte 2, GFPC 03-2019)
2025 · G. Rousseau Bussac, F. Guisier, et al. · Revue des Maladies Respiratoires Actualités
Tolérance et efficacité des thérapies ciblées en post immunothérapie dans les cancers bronchiques non à petites cellules métastatiques avec altérations moléculaires. Étude TOXIMAD GFPC 04-2022
2025 · T. Pierret, J.B. Auliac, et al. · Revue des Maladies Respiratoires Actualités
Hemoptysis Risk in Lung Cancer Associated Thrombosis Patients Who Initiated Anticoagulant Therapy
2025 · Christophe MARIE-SAINTE, Anne-Laure Desage, et al. · SSRN Electronic Journal
Storage of pleural fluid may be crucial for cytological analysis
2024 · Amandine Viccica, Simon Pointel, et al.
Abstract 1221: Selective translational activation of PBK (PDZ- binding kinase) reveals a molecular vulnerability of drug-tolerant persister cells to targeted therapies in EGFR-mutant lung adenocarcinoma
2024 · Camille Leonce, Anne-Laure Désage, et al. · Cancer Research
Works count: 27
Citation count: 187
H-index: 7
I10-index: 7
Year
Topic
Type